AmCad BioMed

AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in the March of 2015 (Ticker: 4188).

AmCad BioMed Corporation is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. The company has successfully developed and commercialized a series of the pioneering, first-in-the-world medical devices.

AmCad’s strong pipeline includes AmCAD-UT (FDA, CE Mark,TFDA and CFDA, for thyroid nodules analysis), AmCAD-UV (CE Mark and FDA, for classifying pulsatile), AmCAD-US (CE Mark and FDA, for backscattered signals analysis), AmCAD-UO (for obstructive sleep apnea detection), AmCAD-CA (for cytopathology analysis) and iSONO Aid (revolutionizing ultrasound imaging). The state-of-the-art pipeline aims for early detection and diagnosis of various types of cancers, such as thyroid cancers, breast cancers, etc., and diseases, including liver fibrosis and obstructive sleep apnea

AmCad’s Blue Ocean Strategy for CAD systems is to develop their own core-technology Platforms by providing high value-added, state-of-the-art image analysis solutions targeting a wide variety of clinical applications and raising the global competition to a higher level

Company’s Keywords:

thyroid cancer detection, obstructive sleep apnea detection, liver fibrosis early detection, breast cancer detection, digital cytology analysis, ultrasound imaging detection, computer assisted detection, computer assisted diagnostics